{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:43:01Z","timestamp":1780602181484,"version":"3.54.1"},"update-to":[{"DOI":"10.1016\/j.ejca.2012.02.053","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000}}],"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ejca.2012.02.053","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T07:02:16Z","timestamp":1331622136000},"page":"1581-1592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["RETRACTED: Effects of the combination of RAD001 and docetaxel on breast cancer stem cells"],"prefix":"10.1016","volume":"48","author":[{"given":"Xiaobei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.02.053_b0005","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2012.02.053_b0010","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.02.053_b0015","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4161\/cc.3.4.795","article-title":"Cancer stem cells persist in many cancer cell lines","volume":"3","author":"Setoguchi","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejca.2012.02.053_b0020","article-title":"The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells","author":"Ma","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2012.02.053_b0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1593\/tlo.09277","article-title":"Biomarker development for the clinical activity of the mTOR inhibitor Everolimus (RAD001): processes, limitations, and further proposals","volume":"3","author":"O\u2019Reilly","year":"2010","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2012.02.053_b0030","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2012.02.053_b0035","first-page":"171","article-title":"Headway in resistance to endocrine therapy in breast cancer","volume":"2","author":"Xu","year":"2010","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2012.02.053_b0040","first-page":"100","article-title":"The role of survivin in diagnosis, prognosis and treatment of breast cancer","volume":"2","author":"Lv","year":"2010","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ejca.2012.02.053_b0045","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","article-title":"MTOR-targeted therapy of cancer with rapamycin derivatives","volume":"16","author":"Vignot","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.02.053_b0050","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"MTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.02.053_b0055","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1535-7163.MCT-05-0130","article-title":"Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells","volume":"4","author":"Morse","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2012.02.053_b0060","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1101\/gad.1061803","article-title":"In vitro propagation and transcriptional profiling of human mammary stem\/progenitor cells","volume":"17","author":"Dontu","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2012.02.053_b0065","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1158\/0008-5472.CAN-03-3344","article-title":"Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro","volume":"64","author":"Houghton","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2012.02.053_b0070","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.02.053_b0075","doi-asserted-by":"crossref","first-page":"16158","DOI":"10.1073\/pnas.0702596104","article-title":"Activation of the PTEN\/mTOR\/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance","volume":"104","author":"Zhou","year":"2007","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.ejca.2012.02.053_b0080","article-title":"MTOR as a therapeutic target in patients with gastric cancer","author":"Al-Batran","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2012.02.053_b0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","article-title":"Mechanisms of mTOR inhibitor resistance in cancer therapy","volume":"6","author":"Carew","year":"2011","journal-title":"Target Oncol"},{"key":"10.1016\/j.ejca.2012.02.053_b0090","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1074\/jbc.M309999200","article-title":"AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression","volume":"279","author":"Gera","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2012.02.053_b0095","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2012.02.053_b0100","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.02.053_b0105","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"MTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2012.02.053_b0110","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2012.02.053_b0115","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1371\/journal.pmed.0050008","article-title":"Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma","volume":"5","author":"Cloughesy","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2012.02.053_b0120","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2012.02.053_b0125","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2012.02.053_b0130","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nchembio.183","article-title":"Inhibitor hijacking of Akt activation","volume":"5","author":"Okuzumi","year":"2009","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.ejca.2012.02.053_b0135","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1471-2407-10-287","article-title":"Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations","volume":"10","author":"Krech","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2012.02.053_b0140","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1593\/neo.09620","article-title":"Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts","volume":"11","author":"Koskimaki","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejca.2012.02.053_b0145","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2012.02.053","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000}},{"DOI":"10.1016\/j.ejca.2026.116733","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000}},{"DOI":"10.1016\/j.ejca.2026.116733","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912002055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912002055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:36:16Z","timestamp":1775583376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912002055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0959804912002055"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.02.053","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Effects of the combination of RAD001 and docetaxel on breast cancer stem cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2012.02.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}